<DOC>
	<DOCNO>NCT02378701</DOCNO>
	<brief_summary>The goal research study test quality-of-life questionnaire call QUALMS-1 patient MDS .</brief_summary>
	<brief_title>Interventional Validation MDS-Specific Measure Quality Life : Assessing Responsiveness Quality Life Myelodysplasia Scale ( QUALMS-1 ) Different Hypomethylating Agent Regimens Low Intermediate Risk Disease</brief_title>
	<detailed_description>If agree take part study , ask complete questionnaire twice participation 2014-0112 study . During first treatment visit , ask complete QUALMS-1 questionnaire another questionnaire ask well-being . After 4th cycle treatment stop receiving treatment , ask complete QUALMS-1 questionnaire another questionnaire rate change health since start study . It take 20 minute total complete questionnaire time . Information also collect medical record . This information include result lab test information relate health . Length Study Participation : After complete questionnaire second time , participation study complete . This investigational study . Up 240 participant enrol multicenter study . Up 40 take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Sign Institutional Review Board ( IRB ) approve informed consent document . 2 . Age great equal 18 year 3. de novo secondary International Prognostic Scoring Status ( IPSS ) low intermediate1risk MDS , include Chronic Myelomonocytic Leukemia ( CMML ) 1 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status great equal 3 study entry 5 . Organ function define : Serum creatine great equal mg/dL x upper limit normal ( ULN ) ; Total bilirubin great equal 2 x ULN ; Alanine transaminase ( ALT ; Serum glutamic pyruvic transaminase=SGPT ) great equal 2 x ULN 6 . Women childbearing potential must negative serum urine pregnancy test within 7 day also need use contraceptive . Men must agree father child agree use condom partner child bear potential . 1 . Breast feeding female 2 . Prior therapy decitabine azacitidine 3 . Prior participation development QUALMS1 ( DanaFarber Cancer Institute=DFCI ) 4 . NonEnglish speaking patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Low- intermediate-1-risk</keyword>
	<keyword>Chronic Myelomonocytic Leukemia -1</keyword>
	<keyword>CMML-1</keyword>
	<keyword>Quality Life Myelodysplasia Scale</keyword>
	<keyword>QUALMS-1</keyword>
	<keyword>Anemia Subset FACT</keyword>
	<keyword>FACT-An</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>